- Home
- HYPR vs SERA Comparison
HYPR vs SERA Comparison
Compare HYPR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | SERA |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 90.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYPR | SERA |
|---|---|---|
| Price | $0.94 | $2.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.28 | N/A |
| AVG Volume (30 Days) | ★ 475.0K | 33.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,591,000.00 | $95,000.00 |
| Revenue This Year | $12.80 | $217.92 |
| Revenue Next Year | $36.09 | $479.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $0.53 | $1.37 |
| 52 Week High | $2.22 | $9.13 |
Technical Indicators
Market Signals| Indicator | HYPR | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 36.64 | 41.38 |
| Support Level | $1.00 | $3.20 |
| Resistance Level | $1.18 | $3.56 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 3.55 | 19.54 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.